University: University of St Andrews

Sector(s): Life Sciences

Key Benefits:

• Biochemical screening assay based upon the interaction between picornavirus protein 2C and dual specificity kinase anchoring protein AKAP10 (D-AKAP2)
• Readily available and inexpensive materials
• Established protocol;Identifies hit and lead candidates for further development.

Applications:

• The assay can be used to screen both peptides and non-peptidal compounds.
• The assay is a versatile technology and is applicable to the following picornaviruses: aphthoviruses, rhinoviruses, cardioviruses, enteroviruses, parechoviruses and hepatoviruses. In addition, it can also be applied to the following calciviruses: Feline Calcivirus (FECV); and Southampton virus (SV). Such diverse applications may prove to be of substantial benefit to pharmaceutical and biotechnology companies which screen peptides and non-peptidal compounds to select novel antiviral agents for further development

IP Status:

The University of St. Andrews has been granted European (No. 1342084B) and US (No. 7,148,022) patent protection. As yet, there are no commercial parties involved. The University would welcome enquiries from commercial parties interested in entering into a licensing arrangement.